Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02935647 · ClinicalTrials.gov registry record · Phase 1

Burst Suppression Anesthesia for Treatment of Severe Depression

A Phase 1 study of Major Depressive Disorder, sponsored by University of Utah.

Completed
Registry status
Phase 1
Development phase
11
Enrollment target
1
Study location

NCT02935647 is a Phase 1 study of Major Depressive Disorder that has completed, run by University of Utah. The registered enrollment target is 11 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02935647, a Phase 1 study of Major Depressive Disorder, has completed, sponsored by University of Utah.

COMPLETED
Registry status
Phase 1
Development phase
11 participants
Enrollment target
1
Study location

Study Summary

This study is designed to determine if the antidepressant effects of deep anesthesia via propofol are related to EEG burst suppression.

Conditions Studied

Interventions

  • DRUG Diprivan

Study Locations (1)

Utah

  • University Neuropsychiatric Institute - Salt Lake City

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2016-10-01
Est. Completion 2018-09
Phase Phase 1

Sponsor

University of Utah

818 total trials

What the Registry Record Tells You About NCT02935647

The ClinicalTrials.gov registry entry for NCT02935647 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (97% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Diprivan is the first listed.

NCT02935647 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.

Frequently Asked Questions

What is clinical trial NCT02935647 about?

NCT02935647 is a clinical study titled "Burst Suppression Anesthesia for Treatment of Severe Depression". This study is designed to determine if the antidepressant effects of deep anesthesia via propofol are related to EEG burst suppression.

What is the current status of trial NCT02935647?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2016-10-01. Estimated completion is 2018-09.

What conditions does trial NCT02935647 study?

This clinical trial studies the following conditions: Major Depressive Disorder.

What interventions are being tested in trial NCT02935647?

The interventions under investigation include: Diprivan (DRUG).

Who is sponsoring clinical trial NCT02935647?

This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02935647 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Major Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.